Zongertinib-Hernexeos common side effects and safe medication reminders

Zongertinib (trade name: Hernexeos) is a tyrosine kinase inhibitor that targets HER2 (ERBB2). Oral small molecule targeted drugs with mutations in the amino acid kinase domain (TKD) are mainly used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC). As a new generation of targeted drugs, Hernexeos has shown high efficacy in clinical trials, but it also has a certain risk of side effects. Understanding its common side effects and safe medication precautions is of great significance for patients to ensure efficacy and safety during use.

First, common side effects of Hernexeos include digestive system reactions, blood system abnormalities, skin reactions, and mild cardiovascular effects. Digestive system reactions are one of the most common side effects of Hernexeos, and patients may experience symptoms such as nausea, vomiting, diarrhea, or loss of appetite. Usually, such symptoms can be relieved by adjusting diet, taking medication in divided doses, or using symptomatic drugs. However, if symptoms persist or worsen, you should seek medical treatment in time. Blood system abnormalities include thrombocytopenia, leukopenia, etc., which may increase the risk of infection or bleeding. Therefore, regular blood routine monitoring is required during the use of Hernexeos in order to detect abnormalities early and take corresponding treatment measures.

Secondly, skin reactions are also common adverse reactions ofHernexeos, mainly manifesting as rash, itching or dryness. In some patients, skin reactions may be more obvious, affecting daily life and medication compliance. To relieve skin discomfort, patients can use mild skin care products, avoid sun exposure, and use topical medications as directed by their doctor. At the same time, mild effects on the cardiovascular system, such as increased blood pressure and changes in heart rhythm, also require attention, especially in patients with a history of previous cardiovascular disease. If necessary, electrocardiogram monitoring should be performed, and drug dosage or intervention measures should be adjusted under the guidance of a doctor.

In terms of safe medication, the use of Hernexeos must follow the guidance of a doctor and be taken strictly in accordance with the recommended dosage and medication time. Patients should avoid stopping the medication on their own or adjusting the dose arbitrarily while taking the medication to prevent the efficacy from being affected or the risk of side effects being increased. If serious adverse reactions occur, you should contact your doctor immediately and consider adjusting the treatment plan. At the same time, patients should pay attention to a balanced diet, adequate rest and moderate exercise in daily life to enhance physical fitness and drug resistance. In addition, since Hernexeos has not yet been launched in China, patients must ensure that the source of drugs is formal when obtaining drugs through overseas channels to avoid risks caused by counterfeit drugs or improper transportation.

Overall, zongatinib (Hernexeos) provides a new treatment option for patients with HER2 mutationsNSCLC, but side effects such as digestive system reactions, blood system abnormalities, skin reactions and cardiovascular effects may occur during use. Through regular monitoring, symptomatic treatment, and taking medications as directed by your doctor, you can minimize risks and ensure efficacy. At the same time, patients should choose formal channels to obtain drugs and pay attention to drug launches and medical insurance developments in order to obtain the best treatment effect under the premise of safety and controllability.

Reference link:https://www.drugs.com